# Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

> **NCT00039182** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (actual)

## Conditions studied

- Advanced Malignant Mesothelioma
- Epithelial Mesothelioma
- Recurrent Malignant Mesothelioma
- Sarcomatous Mesothelioma

## Interventions

- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00039182
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039182, "Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00039182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*